(4-Bromophenyl) hypoiodite

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-Bromophenyl) hypoiodite
• 英文别名: (4-bromophenyl) hypoiodite
• 化学式: C₆H₄BrIO
• 分子量: 298.9
• InChiKey: LYJSBRKEAKGYDX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] S1P AND/OR ATX MODULATING AGENTS<br/>[FR] AGENTS MODULANT S1P ET/OU ATX
  申请人：BIOGEN IDEC INC

  公开号：WO2014081752A1

  公开（公告）日：2014-05-30

  Compounds of formula (I) wherein: X is -0-, -S(0)r-, -CH2-, or -NR-, wherein r is 0, 1, or 2; X 1, X2, and X5 are each independently CR7 or N; one of X3 or X4 is C and is attached by a single bond to -L-, and the other is CR7 or N, provided that no more than three of X1, X2, X3, X or X5 are N; Ring A is monocyclic C5-6scycloalkyl or a 5- to 6-membered monocyclic heterocyclyl comprising from 1 to 5 heteroatoms independently selected from N, S, or 0; wherein Ring A is further optionally substituted with from 1 to 3 R4; provided that Ring A is not morpholinyl, thiomorpholinyl or tetrahydro-2H-pyranyl; L is a bond, -0-, -NR-, -S(0)n-, -CH2-,or -C(O)-, wherein n is 0, 1, or 2; 1 2 L1 is an C1-8alkylene, C3-scycloalkylene, -CH2-L2 -, or a 3- to 8- membered heterocyclylene comprising 1 to 5; R1 is C6-20alkyl or a monocyclic C3-8cycloalkyl; wherein said C3-8cycloalkyl is substituted with at least one R6 and may be optionally substituted with from 1 to 5 additional R6 substituents, wherein R6 for each occurrence is independently selected; and R2 is -C(0)OR3, -C(0)N(R3)-S(0)2R3, -S(0)2OR3, -C(0)NHC(0) R3, -Si(0)OH, - B(OH)2, -N(R3)S(0)2R3, -S(0)2N(R3)2, -O-P(O) (OR3)2, or -P(0)(OR3)2, -CN, - S(0)2NHC(0)R3, -C(0)NHS(0)2R3, - C(0)NHOH, -C(0)NHCN, -CH(CF3)OH, -C(CF3)2OH, or a selected heteroaryl or heterocyclyl; and pharmaceutically acceptable salts thereof, can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).

  式(I)的化合物，其中：X为-0-，-S(0)r-，-CH2-或-NR-，其中r为0、1或2；X1、X2和X5分别独立为CR7或N；X3或X4中的一个为C，并通过单键连接到-L-，另一个为CR7或N，前提是X1、X2、X3、X或X5中不超过三个为N；环A为单环C5-6脂环烷基或由1至5个杂原子（独立选择自N、S或0）构成的5至6成员单环杂环烷基；其中环A还可选择地取代1至3个R4；前提是环A不是吗啉基、硫吗啉基或四氢-2H-吡喃基；L为键、-0-、-NR-、-S(0)n-、-CH2-或-C(O)-，其中n为0、1或2；L1为C1-8烷基、C3-脂环烷基、-CH2-L2-或由1至5个杂原子构成的3至8成员杂环亚烷基；R1为C6-20烷基或单环C3-8脂环烷基；其中所述的C3-8脂环烷基被至少一个R6取代，并且可以选择地取代1至5个额外的R6取代基，其中每次出现的R6独立选择；R2为-C(0)OR3、-C(0)N(R3)-S(0)2R3、-S(0)2OR3、-C(0)NHC(0)R3、-Si(0)OH、-B(OH)2、-N(R3)S(0)2R3、-S(0)2N(R3)2、-O-P(O)(OR3)2、或-P(0)(OR3)2、-CN、-S(0)2NHC(0)R3、-C(0)NHS(0)2R3、-C(0)NHOH、-C(0)NHCN、-CH(CF3)OH、-C(CF3)2OH，或所选的杂芳基或杂环基；及其药学上可接受的盐，可以调节一个或多个SIP受体的活性和/或自动税脂酶（ATX）的活性。
• INHIBITORS OF PROTEIN PRENYLTRANSFERASES
  申请人：Kwon Ohyun

  公开号：US20110178138A1

  公开（公告）日：2011-07-21

  The present invention is directed to novel compounds. These compounds can be useful in inhibiting the activity of protein prenyltransferases including GGTase I and/or RabGGTase. The compounds can also be used as anti-cancer therapeutics including as part of methods for treating cancer, in assays, and in kits.